Results 251 to 260 of about 295,608 (311)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus. [PDF]

open access: yesLupus Sci Med
Martins E   +13 more
europepmc   +1 more source

Italian Olfactory Identification Test in Systemic Lupus Erythematosus: Association of Olfactory Impairment With Chronic Damage and Anti-β<sub>2</sub>-Glycoprotein I Antibodies. [PDF]

open access: yesACR Open Rheumatol
Di Berardino M   +11 more
europepmc   +1 more source

O36 HPV vaccination and cervical screening in SLE patients

open access: yesLupus Science and Medicine
Myles Lewis   +9 more
doaj   +1 more source

A Case of Longitudinal Extensive Transversal Myelitis in Patient With Neuromyelitis Optica Spectrum Disorder and Systemic Lupus Erythematosus. [PDF]

open access: yesClin Case Rep
Pravdic N   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy